| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 75.58 | 4.0% | 27.0% |
| Total Income | 76.57 | 3.8% | 27.4% |
| Expenditure | 65.60 | 2.9% | 26.0% |
| PBT | 10.97 | 9.0% | 36.3% |
| Net Profit | 8.14 | 7.8% | 36.0% |
| OPM | 30.68% | 0.05pp | 36.33pp |
| NPM | 10.63% | 0.46pp | 0.67pp |
| EPS | 1.56 | 9.8% | 32.2% |
Suraksha Diagnostic Reports 30.3% Y-o-Y Growth in Q3 FY26 Total Income
05 Feb 2026 · 5 Feb, 5:23 pm
Summary
Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter and nine months ended 31 December 2025. The company reported a 30.3% year-on-year growth in total income in Q3 FY26, with EBITDA growing by 26.1% year-on-year.
Key Highlights
- 1
Total Income grew by 30.3% year-on-year in Q3 FY26
- 2
Q3 FY26 EBITDA grew by 26.1% year-on-year
- 3
In 9M FY26, the company added 12 operational centres and 6 under development
- 4
Launched Suraksha Sutra, the Genomics/Molecular vertical, securing a strong first-mover advantage in Eastern India
Management Comments
Mrs. Ritu Mittal
We continued to generate strong quarterly top-line growth in Q3 FY26 on the back of our robust network expansion. The EBITDA margin impact was attributable to the launch and development of new centres. Our centres which are > 2 years old continue to operate at a strong 37% EBITDA, indicating the strength of our business model. We are ‘Investing for Scale: Short-term Compression for Long -term Dominance’.
Informational and educational content only. Not investment advice.